DCGI asks Serum Institute to revise protocol for phase 2, 3 trials of Oxford COVID-19 vaccine

A CDSCO expert panel has sought clarifications from Serum Institute of India (SII) over its application to the DCGI seeking permission for conducting phase 2 and 3 human clinical trials of the Oxford vaccine candidate for COVID-19, official sources said on Wednesday. On Wednesday evening, SII submitted a revised protocol for conducting the trials to the DCGI.